# *Emerging-Trends:* Executive Laser Report OPHTHALMIC AND MEDICAL LASER HIGHLIGHTS January 2013

**Volume VIII No. 1** 

laser@emerging-trends.com

February 15, 2013

Here are the January highlights, and we hope that you're staying warm this winter. Please consider subscribing to *Executive Laser Report* and to our sister publication, *Trends-in-Medicine*.

## **OPHTHALMIC LASER HIGHLIGHTS**

### **Financial News**

- **Bausch** + Lomb completed its acquisition of **Technolas Perfect Vision**. The Bausch + Lomb and Technolas Perfect Vision pairing will be called Bausch + Lomb Technolas. In other news, *Bloomberg* reported that at least three big healthcare firms are considering the purchase of Bausch + Lomb. Potential buyers are said to include Abbott Laboratories, Johnson & Johnson, and Sanofi.
- **Iridex** said that it had preliminary revenue of approximately \$9.2 million and \$33.8 million for 4Q12 and full-year 2012, respectively. 4Q12 revenue exceeded the high end of the company's prior guidance and was driven by a healthy uptick in sales of laser systems.

### **Other News**

- Alcon is under investigation relating to the export of its products to various countries subject to US trade sanctions, including Iran.
- **Bausch** + Lomb notified healthcare professionals of a Class I recall of certain Bausch + Lomb 27G sterile cannula, which may leak viscoelastic material or detach from the syringe during injection. In some rare incidences, detachment resulted in serious patient injury.
- The Medical Technology business group of **Carl Zeiss Meditec** is presenting the new Forum Viewer app at the 28<sup>th</sup> Congress of the Asia-Pacific Academy of Ophthalmology (APAO) in Hyderabad, India. The app provides doctors with mobile access to the medical findings and reports stored in Forum.
- LCA-Vision said that 11,613 procedures were performed during 4Q12 vs. 14,205 procedures performed during 4Q11.

## MEDICAL/SURGICAL LASER HIGHLIGHTS

#### **Financial News**

• AngioDynamics' financial results for 2Q13, which ended November 30, showed increases in net sales compared to 2Q12 but a drop in net income. In other news, the company is buying certain assets of Microsulis Medical.

2731 N.E. Pinecrest Lakes Blvd. Jensen Beach, FL 34957 772-334-7409 • Fax 772-334-0856 www.emerging-trends.com

Publisher: Stephen Snyder Managing Editor: Michael Woods Contributing Editor: D. Woods Editor: Betty Teel The information and opinions expressed in Executive Laser Report have been compiled or arrived at from sources believed to be reliable and in good faith, but no liability is assumed for information contained in this newsletter. Copyright © 2013. This document may not be reproduced without written permission of the publisher.

- **Biolase** said that, based on preliminary unaudited financial results, the company expects to report that it generated positive cash flow from operations in 4Q12.
- Monteris Medical closed a \$7.8 million financing round to support continued commercialization of the NeuroBlate system in the North American neurosurgery market.
- Novartis said that 4Q12 net sales were up 2% vs. 4Q11, despite patent expirations, and predicted a new growth phase in 2013.
- **Spectranetics** is buying Upstream Peripheral Technologies, an affiliate of ARAN Research Development & Prototypes, for \$5.5 million.

### **Other News**

- Abbott is once again in the S&P 500 Dividend Aristocrats and S&P High Yield Dividend Aristocrats Indices. In other news, Abbott completed the separation of its research-based pharma business, which became AbbVie, a new independent biopharmaceutical company.
- The FDA issued a warning to **Meridian** following an inspection of the company's factory in Switzerland, saying that the company did not adequately respond to five citations including failure to establish and maintain procedures to control product.
- Final results from a trial looking at **Spectranetics**' Turbo-Booster and excimer laser for in-stent restenosis treatment appear to be promising.

٠